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INTRODUCTION
Idiopathic interstitial pneumonias (IIPs) are a group of hetero-
geneous diffuse parenchymal lung disorders of unknown etiology.
Idiopathic pulmonary fibrosis (IPF) is the most common form of
IIP, and has an extremely poor prognosis (1, 2). Acute exacerbation
(AE) of IPF (AE-IPF) is acute respiratory deterioration without
clinically apparent left heart failure, pulmonary embolism, or other
identifiable causes (3). Acute exacerbation occurs mostly in IPF,
although it also occurs in other fibrosing interstitial pneumonias
such as idiopathic nonspecific interstitial pneumonia (iNSIP) (2).
The prognosis of AE-IPF is exceedingly severe. Some studies in-
dicate that the in-hospital survival rate of AE-IPF is 40%-50% (4, 5).
Corticosteroids and/or immunosuppressive agents are adminis-
tered to patients with AE-IPF. However, there is no reliable data
to support their efficacy.
Some papers indicate that direct hemoperfusion with polymyxin
B-immobilized fiber (PMX) may improve oxygenation and survival
in patients with AE-IPF or other rapidly progressive interstitial
pneumonias (6, 7). Abe et al. reported that the 30-day survival rate
of PMX treatment for AE-IPF was 70.1% (6). On the other hand,
recombinant human thrombomodulin (rhTM) may also improve
the survival of AE-IPF patients : Kataoka et al. reported that the
3-month survival rate of rhTM therapy was 70% (8). These treat-
ments are greatly expected to be useful modalities for treating AE-
IPF, although it is necessary to confirm their efficacy in further
large-scale prospective studies.
Leukocytapheresis (LCAP) is a procedure that removes leuko-
cytes during extracorporeal circulation. It has been proven that
LCAP effectively treats patients with rheumatoid arthritis and ul-
cerative colitis (9, 10). Moreover, some reports indicate its efficacy
in patients with progressive interstitial pneumonia (IP) associated
with polymyositis or dermatomyositis (11, 12). The effectiveness
of LCAP is through the removal of activated leukocytes (13). Some
investigators have observed activated leukocytes such as neutro-
phils and macrophages in patients with AE of IIPs (AE-IIPs) (3, 14).
Therefore, we hypothesized that LCAP may improve the general
and respiratory condition of patients with AE-IIPs.
In this study, we investigated whether LCAP could improve the
30-day survival of patients with AE-IIPs. To evaluate the efficacy of
LCAP, we also observed oxygenation, high-resolution computed
tomography (HRCT) findings, and the serum or plasma levels of
certain chemical mediators.
PATIENTS AND METHODS
Six patients with AE-IPF or AE of iNSIP were enrolled in this
open- label pilot study of LCAP therapy. Idiopathic pulmonary fi-
brosis was diagnosed, based on HRCT criteria alone in accordance
with the 2011 official American Thoracic Society/European Res-
piratory Society/Japanese Respiratory Society/Latin American
Thoracic Association statement (1). All four of the following HRCT
findings were required for a diagnosis of IPF : (1) subpleural and
basal predominance ; (2) reticular abnormalities ; (3) honeycomb-
ing with or without traction bronchiectasis ; and (4) absence of
features inconsistent with usual interstitial pneumonia pattern.
Surgical lung biopsies remain the gold standard for the differential
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diagnosis of IIPs. However, it is difficult to perform this procedure
in many patients with AE because of the severity of the disease.
Therefore, in this study, we clinically defined iNSIP as IP with the
typical HRCT pattern of NISP and without any other causes of inter-
stitial lung disease. According to previous reports, typical HRCT
findings of NSIP are bilateral, symmetric, predominantly lower
lung reticular opacities with traction bronchiectasis and lower lobe
volume loss (2, 15, 16). In all patients, other causes of interstitial
lung disease such as occupational or environmental exposure, con-
nective tissue disease, and drug- induced pneumonia were strictly
excluded, based on their medical histories and clinical examina-
tions.
An AE was defined, as follows : worsening dyspnea within days
to weeks ; evidence of abnormal gas exchange, as defined by a low
partial pressure of arterial oxygen (PaO2)/percentage of inspired
oxygen ratio (P/F ratio) or a decrease in the PaO2 ; new radio-
graphic opacities ; and the absence of an alternative explanation
such as infection, left heart failure, or pulmonary embolism (3). All
of the aforementioned criteria were satisfied in each patient in this
study. Ultrasound cardiography was performed to rule out conges-
tive heart failure. All patients had no evidence of left ventricular
dysfunction. Cultures of sputum, blood, and urine were examined
for bacteria, fungi and mycobacteria, and were negative in all pa-
tients.
Leukocytapheresis was performed using a leukocyte removal fil-
ter (CS-180S, Cellsorba ; Asahi Kasei Medical Co., Tokyo, Japan).
For venous access, a double- lumen catheter was inserted into the
internal jugular vein under ultrasound guidance. Leukocytaphere-
sis was performed on days 2, 3, 9 and 10. During each apheresis
procedure, 3000 mL of whole blood was filtered and processed for
60-90 minutes using a blood pump at a speed of 30-50 mL/min.
All patients received a continuous intravenous infusion of low-
molecular -weight heparin (i.e., dalteparin sodium) at a dose of
75 IU/kg/day between days 1 and 14. All patients were treated with
intravenous methylprednisolone pulse therapy (1000 mg/day on
days 1-3 and 8-10), followed by oral prednisolone (1 mg/kg/day
on days 4-7). The dosage of corticosteroids was gradually tapered
after the second methylprednisolone pulse therapy. Specific neu-
trophil elastase (i.e., sivelestat sodium) and immunosuppressive
agents were prohibited on days 1-10.
To evaluate the severity of the patients’ general condition, we
used the Sequential Organ Failure Assessment (SOFA) score on
the admission of each patient. To evaluate the efficacy of LCAP
therapy, we observed 30-day survival after the diagnosis of AE.
High-resolution computed tomography scans were performed in
the pre- and post-LCAP terms. The alveolar -arterial difference in
oxygen (AaDO2) and the P/F ratio were calculated, based on the
arterial blood gas analysis in both LCAP terms. Furthermore, we
measured the serum levels of lactate dehydrogenase (LDH), sur-
factant protein (SP)-A, SP-D, Krebs von der Lugen-6 (KL-6),
which may be useful biomarkers of IIPs. In the pre- and post-LCAP
terms, we also determined the serum levels of interleukin (IL)-6,
IL-18, tumor necrosis factor -alpha, interferon-gamma, monocyte
chemotactic protein 1 (MCP-1), and high mobility group box-1
(HMGB-1), and the plasma levels of IL-8 and transforming growth
factor-beta 1, which may have roles in AE-IIPs (17-21). Further-
more, we validated the safety of LCAP therapy through the verifi-
cation of adverse events.
Written informed consent was obtained from all patients. The
study was approved by the Ethics Committee of Tottori University
Medical Department (Yonago, Japan).
All data were analyzed using the IBM SPSS Statics software ver-
sion 23.0 for windows (IBM SPSS, Tokyo, Japan). We used the
Wilcoxon signed-rank test to calculate statistical significance. Val-
ues of p0.05 were defined as statistically significant.
RESULTS
The clinical characteristics of the patients with AE-IIPs are shown
in Table 1. Between February 20, 2014, and September 14, 2015,
six patients (five men, one woman) were enrolled in this study. The
median age was 70 years (range, 65-83 years). The diagnosis was
IPF for five patients and iNSIP in the other patient. Case 1 and 2 had
received no previous therapy. Pirfenidone (1800 mg/day) had been
administered to Cases 3, 5 and 6. Cases 4 and 5 had received oral
prednisolone (7 mg/day and 20 mg/day, respectively). The aver-
age duration from the first radiologic abnormality to AE was 53
months (range, 25-105 months). The median SOFA score was 2
points (range, 1-3 points). The median P/F ratio and AaDO2 were
271 (range, 205-304) and 53.5 mmHg (range, 35.0-97.2 mmHg),
respectively. Before LCAP, the serum levels of LDH (normal
range,229 IU/mL), KL-6 (normal range,500 IU/mL) and SP-A
(normal range,43.8 ng/mL) were elevated in all six patients.
The clinical course of each patient is summarized in Figure 1.
For all patients, we performed LCAP therapy, corticosteroid ther-
apy, and a continuous intravenous infusion of low-molecular -weight
heparin in compliance with the protocol. Five of six patients (Cases
1, 2, 3, 4 and 6) survived for more than 30 days after the diagnosis
of AE. One patient (Case 5) died of progressive respiratory failure
on hospital day 16. In Case 6, the recurrence of AE-IPF was ob-
served on day 49. He had been treated with intravenous methyl-
prednisolone pulse therapy (1000 mg/day daily), followed by intra-
venous prednisolone (1 mg/kg/day) after the recurrence. He died
of respiratory failure on day 57. No recurrence of AE-IIPs was
observed in Case 1, 2, 3 and 4 at least for a year. The AaDO2 im-
proved after LCAP therapy, except for Case 5. In addition, the serum
level of LDH decreased after LCAP therapy in all survivors. We














1 70/M 105 2 238 60.4 384 1377 221.0 IPF None
2 83/F 48 1 304 41.3 318 524 80.8 IPF None
3 65/M 35 2 297 35.0 250 611 60.8 IPF PFD
4 67/M 25 2 264 71.0 340 712 96.0 iNSIP PSL+CsA
5 70/M 83 3 205 97.2 400 1865 134.0 IPF PSL+PFD
6 74/M 58 3 278 46.6 414 2669 82.7 IPF PFD
AaDO2 : alveolar -arterial difference of oxygen, AE-IIPs : acute exacerbation of idiopathic interstitial pneumonias, CsA : cyclosporine, Duration :
Duration from diagnosis, F : female, iNSIP : idiopathic nonspecific interstitial pneumonia, IPF : idiopathic pulmonary fibrosis, KL-6 : Krebs von
der Lugen-6, LDH : lactate dehydrogenase, M : male, P/F : partial pressure of arterial oxygen/percentage of inspired oxygen (PaO2/FiO2) ratio,
PFD : pirfenidone, PSL : prednisolone, SOFA score : Sequential Organ Failure Assessment score, SP-A : surfactant protein -A
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used immunosuppressive agents in three patients (Cases 3, 4 and
6) after hospital day 11. Pirfenidone was continued in all three pa-
tients after the onset of the AE (Cases 3, 5 and 6).
Diffuse parenchymal opacifications that were consistent with
AE were newly observed on HRCT before LCAP in all patients.
This finding tended to improve after LCAP therapy in the five sur-
vivors. We show a representative patient in Figure 2.
We validated the P/F ratio and the serum or plasma level of LDH,
SP-A, SP-D, KL-6 and other chemical mediators in the pre- and
post-LCAP terms (Figure 3). In the post LCAP term, the P/F ratio
was improved in all five survivors. The serum level of LDH sig-
nificantly improved statistically in all patients in the post-LCAP
term (p=0.028). The serum levels of SP-A and SP-D tended to im-
prove in the survivors after LCAP therapy. In the post-LCAP term,
the serum levels of HMGB-1 and IL-18 significantly decreased
statistically in all patients (p=0.028 and p=0.027, respectively). By
contrast, we could observe no such tendency in the level of KL-6,
IL-6, IL-8, tumor necrosis factor -α, interferon-γ, MCP-1, and
Figure 1. The clinical course of the patients. Five of six patients (Cases 1, 2, 3, 4 and 6) survived for more than 30 days after the diagnosis of AE.
One patient (Case 5) died of progressive respiratory failure on hospital day 16. The AaDO2 improved after LCAP treatment, except for the one
fatal case. In addition, the serum level of LDH tended to decrease after LCAP treatment in all survivors. Corticosteroids were gradually decreased
after LCAP therapy in all patients. After the 11th hospital day, CsA in Case 3, AZA in Case 4, and TAC in Case 6 were used. After the onset of AE,
pirfenidone was continued in three patients (Cases 3, 5 and 6).
AaDO2 : alveolar -arterial difference of oxygen, AE : acute exacerbation, AZA : azathioprine, CsA : cyclosporine, LCAP : leukocytapheresis, LDH :
lactate dehydrogenase, LMWH : low-molecular -weight heparin, mPSL : methylprednisolone, PSL : prednisolone, TAC : tacrolimus, yo : years old
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transforming growth factor-beta 1 between the pre- and post-LCAP
terms (data not shown).
We evaluated the safety of LCAP therapy in this study. Several
mild adverse events were observed in four of six patients. Throm-
bocytopenia (100,000/µL) was observed in four of six patients
after LCAP. We had evaluated complete blood cell count after
every 2 sessions of LCAP. Six instances of thrombocytopenia
(100,000/µL) were observed in total twelve evaluations. Severe
thrombocytopenia (50,000/µL) was observed in two instances.
All four patients recovered at least seven days after LCAP sessions
without any treatment. No major hemorrhage include intracranial
and pulmonary bleeding was seen as a result of the thrombocy-
topenia. A decrease in the blood pressure occurred in three patients.
Their blood pressure recovered after a reduction in the flow rate ;
therefore, no patient required vasopressor treatment. One patient
complained of chest discomfort during the first LCAP procedure.
This complaint was improved by reducing the pump speed from
50 mL/min to 30 mL/min. No patient discontinued LCAP therapy
because of any adverse events due to LCAP therapy.
DISCUSSION
We investigated whether LCAP, which removes activated leu-
kocytes, could be a promising candidate for treating AE-IIPs. In
this open- label pilot study, five of six patients with AE-IIPs survived
for more than 30 days after the diagnosis of AE. Isshiki et al. re-
ported that the 30-day survival rate of the similar severity AE-IPF
patients treated by conventional corticosteroid treatment with low-
molecular -weight heparin was a little less than 60% (22). In our
study, the severity of the patients’ disease was relatively mild.
However, the survival rate of our study was not inferior to that of
conventional corticosteroid treatment with low-molecular -weight
heparin reported by Isshiki et al.Moreover, oxygenation and HRCT
findings were recovered in all survivors. We performed LCAP ther-
apy without any severe adverse effects. Therefore, LCAP appears
to be a safe and effective therapy on AE-IIPs.
In our study, the peripheral blood platelets were decreased and
recovered at least seven days after LCAP sessions without any
treatments. This is similar to the previous studies in patients with
rheumatoid arthritis and ulcerative colitis and healthy volunteers
(23-25). It has been reported that the peripheral blood platelets
were removed while passing through the column (26). We consid-
ered that thrombocytopenia was recovered by producing new plate-
lets in bone marrow. Although it took several days for recovery of
the thrombocytopenia, no hemorrhagic complications were seen
as a result of it.
The serum level of LDH was elevated in the pre-LCAP term and
significantly decreased in the post-LCAP term. The serum levels
of SP-A and SP-D were also elevated in the pre-LCAP term and
tended to decrease in the post-LCAP term. It has been reported
that the serum level of LDH is a useful indicator of lung damage or
Figure 2. The CXR and HRCT images of a representative patient
(Case 6). (A) The CXR image before AE shows bilateral and lower lung field -dominant reticular opacities. (B) The CXR image at the onset of AE
shows newly developed bilateral infiltration. (C) The CXR image shows that the bilateral infiltrations tended to improve after LCAP treatment. (D)
The HRCT image at the stable term before AE shows the features of subpleural reticular abnormalities and a honeycomb- like appearance with
traction bronchiectasis, which are consistent with the UIP pattern. (E) The HRCT image at the onset of AE shows newly developed bilateral and
nonsegmental ground glass opacities. (F) The HRCT image after LCAP treatment shows that the ground glass opacities tended to disappear.
AE : acute exacerbation, CXR : chest X-ray, HRCT : high-resolution computed tomography, LCAP : leukocytapheresis, UIP : usual interstitial
pneumonia
































































































































inflammation ; moreover, LDH is released into the peripheral
blood after somatic cell death (27). On the other hand, SP-A and
SP-D are proteins that are synthesized and secreted by type II al-
veolar epithelial cells (28). We believe that our results of LDH,
SP-A and SP-D are owing to the suppression of parenchymal in-
flammation and damaged pulmonary epithelial cells by LCAP
through the removal of activated leukocytes that produce proin-
flammatory/inflammatory cytokines. We believe that the improve-
ment in the oxygenation and HRCT findings are caused by similar
process of suppression of inflammation through LCAP therapy.
However, we could observe no such tendencies in the level of KL-6
between the pre- and post-LCAP terms. The high-molecular -weight
protein KL-6 (200 kDa and over) is expressed on human MUC-1
mucin and is quite abundant in intra-alveolar epithelial lining fluid
(29). Because of its size and intra-alveolar distribution, the serum
level of KL-6 may become elevated in the relatively late phase of
inflammation after moderate to severe destruction of epithelial
cells has occurred.
The mechanisms by which PMX treatment improves patients
with AE are unclear ; however, various circulating molecules (e.g.
MCP-1, HMGB-1, neutrophilic elastase, and IL-8) are decreased
by the treatment (30-32). In this study, we also measured certain
chemical mediators to investigate the mechanism of the efficacy
of LCAP. We observed a statistically significant decrease in the
serum level of HMGB-1 and IL-18 between the pre- and post-
LCAP terms. The nuclear protein HMGB-1 (approximately 30 kDa)
is actively secreted from leukocytes (20, 33), and may have im-
portant roles in modulating acute lung inflammation (20, 33, 34).
Furthermore, it has been demonstrated that intraperitoneal injec-
tions of anti -HMGB-1 antibody significantly attenuated lung in-
flammation in murine models (35). On the other hand, IL-18 is
reportedly an inflammatory cytokine synthesized and secreted by
leukocytes (36). It is expressed in most pulmonary cells, especially
by fibroblastic foci, alveolar macrophages, and interstitial mono-
nuclear cells of patients with IPF (21). He and colleagues reported
that the secretion of IL-18 in THP-1 macrophages cultured with
HMGB-1 and ATP showed significantly increased expression (37).
In addition, HMGB-1 functions as a negative regulator of the in-
flammasome activation pathway in which caspase-1 is activated to
promote the maturation of IL-18 (38). Therefore the linkage be-
tween HMGB-1 and IL-18 is not yet fully understood. However,
it is possible that they have cooperative roles in pulmonary pa-
renchymal inflammation. A significant decrease in the levels of
HMGB-1 and IL-18 in the post-LCAP term can be caused by their
anti - inflammatory cooperation during LCAP therapy. We also con-
sider that HMGB-1 and IL-18 may be the therapeutic target mole-
cules in patients with AE-IIPs.
Several researchers report that PMX treatment removed inflam-
matory cells - in particular, activated neutrophils and monocytes,
which produce several inflammatory cytokines (32, 39). On the
other hand, it has been confirmed that LCAP removes activated
leukocytes that produce functional chemical mediators (13, 40).
We believe that it is necessary to compare the efficacy of LCAP
and that of PMX treatment in patients with AE-IIPs. Thrombo-
modulin can bind to HMGB-1, thereby inhibiting inflammation and
coagulation (41, 42), although the previously reported efficacy of
Figure 3. The change between the pre - and post -LCAP terms in the P/F ratio and in the serum levels of the chemical mediators LDH, SP-A, KL-6,
HMGB-1 and IL-18. The serum level of LDH is significantly decreased in the post -LCAP term (p=0.028). In the post -LCAP term, the P/F ratio
and the serum level of SP-A tended to improve in all survivors (Cases 1, 2, 3, 4, and 6). No difference in the level of KL-6 exists between the pre -
and post -LCAP terms. The serum levels of HMGB-1 and IL-18 are significantly decreased statistically in the post -LCAP term (p=0.028 and p=0.027,
respectively).
HMGB-1 : high mobility group box-1, IL -18 : interleukin-18, KL-6 : Krebs von der Lugen-6, LCAP : leukocytapheresis, LDH : lactate dehydro-
genase, P/F ratio : partial pressure of arterial oxygen/percentage of inspired oxygen (PaO2/FiO2) ratio, SP-A : surfactant protein -A
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rhTM in AE-IPF may be related to HMGB-1 inhibition. In the fu-
ture, it is possible that the combined therapy of LCAP and rhTM
will lead to a better prognosis for patients with AE-IIPs.
The recent study has several limitations. First, the number of
patients in this study was very small. Second, although all patients
met the diagnostic criteria for AE, the severity of the patients’ dis-
ease was relatively mild. Third, it is difficult to exclude the effect
of other treatments, especially high-dose corticosteroids, because
this was a single-arm trial.
In this study, we concluded that LCAP could be a safe and ef-
fective procedure to treat the patients with AE-IIPs. A prospective
study on PMX treatment is ongoing. However, we believe that our
findings on LCAP therapy should also be validated in large-scale
controlled trials because there are no established modalities to
treat patients with AE-IIPs.
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